Aurobindo Pharma rises on getting final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray

Aurobindo Pharma

Aurobindo Pharma is currently trading at Rs. 1004.05, up by 14.65 points or 1.48% from its previous closing of Rs. 989.40 on the BSE. The scrip opened at Rs. 1006.45 and has touched a high and low of Rs. 1013.90 and Rs. 996.00 respectively. So far 8516 shares were traded on the counter. The BSE … Read more

Aurobindo Pharma gains after its JV receives SEC recommendation for pneumococcal 15 valent vaccine

aurobindo pharma gets usfdas nod for guaifenesin extended release tablets

Aurobindo Pharma is currently trading at Rs. 442.75, up by 5.50 points or 1.26% from its previous closing of Rs. 437.25 on the BSE. The scrip opened at Rs. 440.40 and has touched a high and low of Rs. 444.80 and Rs. 438.40 respectively. So far 102108 shares were traded on the counter. The BSE … Read more

Aurobindo Pharma jumps on acquiring 51% stake in GLS Pharma

aurobindo pharma surges on its arm agreeing to acquire business assets from profectus biosciences

Aurobindo Pharma is currently trading at Rs. 583.95, up by 3.55 points or 0.61% from its previous closing of Rs. 580.40 on the BSE. The scrip opened at Rs. 579.45 and has touched a high and low of Rs. 586.35 and Rs. 566.60 respectively. So far 98079 shares were traded on the counter. The BSE … Read more

Aurobindo Pharma’s arm receives USFDA’s approval for Cyclophosphamide Injection

aurobindo pharma gets usfdas nod for guaifenesin extended release tablets

Aurobindo Pharma’s subsidiary — Eugia Pharma Specialities (Eugia) has received a 505(b)(2) NDA approval from the U.S.Food & Drug Administration (USFDA) for its Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vials. Aurobindo’s product will be available in ready-to-use (RTU) injection preparation. The product shall be launched in the US market in the near … Read more